

Masateru Ohta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5544806/publications.pdf>

Version: 2024-02-01

40
papers

728
citations

623188

14
h-index

552369

26
g-index

44
all docs

44
docs citations

44
times ranked

772
citing authors

#	ARTICLE	IF	CITATIONS
1	Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2011, 17, 5060-5070.	3.2	158
2	Conformationally Restricted Analogs of 1 α ,25-Dihydroxyvitamin D ₃ and Its 20-Epimer: A Compounds for Study of the Three-Dimensional Structure of Vitamin D Responsible for Binding to the Receptor. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2727-2737.	2.9	69
3	Conformation-Function Relationship of Vitamin D: A Conformational Analysis Predicts Potential Side-Chain Structure. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 1467-1475.	2.9	65
4	kGCN: a graph-based deep learning framework for chemical structures. <i>Journal of Cheminformatics</i> , 2020, 12, 32.	2.8	55
5	Three-dimensional structure-activity relationships and receptor mapping of N1-substituents of quinolone antibacterials. <i>Journal of Medicinal Chemistry</i> , 1991, 34, 131-139.	2.9	44
6	Design of potent K ⁺ channel openers by pharmacophore model. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 625-631.	1.0	30
7	High-Precision Atomic Charge Prediction for Protein Systems Using Fragment Molecular Orbital Calculation and Machine Learning. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 3361-3368.	2.5	22
8	On the side chain conformation of 1 α ,25-dihydroxyvitamin D ₃ responsible for binding to the receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5, 979-984.	1.0	20
9	Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2). <i>Pharmaceutical Research</i> , 2001, 18, 579-586.	1.7	19
10	Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure-Activity Relationships of Its Derivatives. <i>Chemical and Pharmaceutical Bulletin</i> , 2008, 56, 1555-1561.	0.6	19
11	Discovery of 7 α -substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 174-185.	1.4	17
12	Lead Optimization and Avoidance of Reactive Metabolite Leading to PCO371, a Potent, Selective, and Orally Available Human Parathyroid Hormone Receptor 1 (hPTHr1) Agonist. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5089-5099.	2.9	17
13	Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 8150-8157.	1.4	16
14	Structure-activity relationships of 6-substituted benzopyran-4-carbothioamide potassium channel openers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 1659-1662.	1.0	14
15	Factor VIIa inhibitors: Target hopping in the serine protease family using X-ray structure determination. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4533-4537.	1.0	14
16	Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3159-3168.	1.4	14
17	Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5573-5576.	1.0	13
18	Crystal structure of human factor VIIa/tissue factor in complex with peptide mimetic inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2004, 324, 1227-1233.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2005, 327, 589-596.	1.0	11
20	Effects of fluorines on nonsteroidal vitamin D receptor agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 712-721.	1.4	10
21	A series of nonsteroidal vitamin D receptor agonists for osteoporosis therapy. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 1823-1833.	1.4	10
22	Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTH1R) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5949-5962.	2.9	9
23	Comparative molecular field analysis of benzopyran-4-carbothioamide potassium channel openers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1994, 4, 2903-2906.	1.0	8
24	Comprehensive 3D-RISM analysis of the hydration of small molecule binding sites in ligand-free protein structures. <i>Journal of Computational Chemistry</i> , 2020, 41, 2406-2419.	1.5	8
25	Structure-based screening combined with computational and biochemical analyses identified the inhibitor targeting the binding of DNA Ligase 1 to UHRF1. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 52, 116500.	1.4	8
26	Structure of human factor VIIa/tissue factor in complex with a peptide-mimetic inhibitor: high selectivity against thrombin by introducing two charged groups in P2 and P4. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2005, 61, 169-173.	0.7	7
27	Novel interactions of large P3 moiety and small P4 moiety in the binding of the peptide mimetic factor VIIa inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2005, 326, 859-865.	1.0	7
28	CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells. <i>International Journal of Oncology</i> , 2015, 46, 1560-1572.	1.4	7
29	Structure-based design and discovery of novel anti-tissue factor antibodies with cooperative double-point mutations, using interaction analysis. <i>Scientific Reports</i> , 2020, 10, 17590.	1.6	7
30	Background and features of emil, a system for database-aided bioanalogous structural transformation of bioactive compounds. <i>Pharmacochemistry Library</i> , 1995, 23, 235-273.	0.1	6
31	Systematic SAR study of the side chain of nonsteroidal vitamin D3 analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 4495-4506.	1.4	6
32	Structure-Based Drug Design of Peptide Mimetics Containing Large P3 Moieties as Inhibitors of Factor VIIa. <i>Letters in Drug Design and Discovery</i> , 2009, 6, 86-92.	0.4	2
33	Machine learning to estimate the local quality of protein crystal structures. <i>Scientific Reports</i> , 2021, 11, 23599.	1.6	2
34	Design and Synthesis of Peptidomimetic Factor VIIa Inhibitors. <i>Chemical and Pharmaceutical Bulletin</i> , 2010, 58, 38-44.	0.6	1
35	Three-dimensional structure-activity relationships and receptor mapping of quinolone antibacterials. <i>Pharmacochemistry Library</i> , 1995, 23, 97-124.	0.1	0
36	Monte Carlo Simulations on Atropisomerism of Thienotriazolodiazepines Applicable to Slow Transition Phenomena Using Potential Energy Surfaces by ab initio ; Molecular Orbital Calculations. <i>Chemical and Pharmaceutical Bulletin</i> , 2014, 62, 229-237.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Structure-Based Drug Design: A Key Technology for Drug Discovery in the Pharmaceutical Industry. Journal of Cardiac Failure, 2015, 21, S160.	0.7	0
38	Effect of Water Molecules on the Activating S810L Mutation of the Mineralocorticoid Receptor. Journal of Chemical Information and Modeling, 2021, 61, 3583-3592.	2.5	0
39	Abstract A220: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for treatment of castration-resistant prostate cancer. , 2009, , .		0
40	Abstract A219: Universal efficacy of novel androgen receptor pure antagonist, CH5137291, against broad spectrum prostate cancer including castration-resistant prostate cancers. , 2009, , .		0